William E Dager

发表

Systemic anticoagulation considerations in chronic kidney disease.

T. Kiser, Tyree H Kiser, W. Dager, 2010, Advances in chronic kidney disease.

W. Dager, William E Dager, 2003, The Annals of pharmacotherapy.

Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single‐Center Case Series Analysis Including Patients on Hemodialysis

W. Dager, William E Dager, E. A. Walker, 2017, Pharmacotherapy.

Safety of New Oral Anticoagulants with Dual Antiplatelet Therapy in Patients with Acute Coronary Syndromes

W. Dager, William E Dager, L. Tsu, 2013, The Annals of pharmacotherapy.

Pharmacotherapy Considerations in Advanced Cardiac Life Support

J. Tisdale, B. Wiggins, C. Sanoski, 2006, Pharmacotherapy.

ACUTE CORONARY SYNDROME: THE COMMUNITY PHARMACISTS' ROLE IN THE CONTINUUM OF CARE

W. Dager, William E Dager, 2007 .

Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.

W. Dager, William E Dager, C. Kulig, 2020, ASAIO journal.

Use of Lepirudin in Patients with Heparin-Induced Thrombocytopenia and Renal Failure Requiring Hemodialysis

R. White, W. Dager, William E Dager, 2001, The Annals of pharmacotherapy.

Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update

J. H. Maker, Brian M. Hoff, Brett H. Heintz, 2020, The Annals of pharmacotherapy.

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Arthur L. Allen, S. Kaatz, S. Deitelzweig, 2020, Journal of Thrombosis and Thrombolysis.

Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.

J. T. Owings, E. Larkin, R. Gosselin, 2004, American journal of clinical pathology.

Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors

E. V. Van Cott, W. Dager, A. Roberts, 2017, Seminars in Thrombosis and Hemostasis.

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.

G. Grice, W. Dager, William E Dager, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay

D. Dwyre, R. Gosselin, W. Dager, 2013, The Annals of pharmacotherapy.

Removal of dabigatran by hemodialysis.

W. Dager, A. Chin, William E Dager, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban

E. Hawes, R. Gosselin, S. Moll, 2015, The Annals of pharmacotherapy.

Critical Pathways: The Role of Pharmacy Today and Tomorrow

B. Zarowitz, P. Dobesh, J. Bosso, 2006, Pharmacotherapy.

The Need for PGY2‐Trained Clinical Pharmacy Specialists

John E. Murphy, P. Gubbins, K. Ragucci, 2014, Pharmacotherapy.

Ximelagatran: An Oral Direct Thrombin Inhibitor

E. Nutescu, T. Vondracek, W. Dager, 2004, The Annals of pharmacotherapy.

Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation

W. Dager, William E Dager, 2004, Journal of cardiovascular pharmacology and therapeutics.

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

J. Douketis, C. Samama, A. Dunn, 2022, Chest.

Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline Executive Summary.

J. Douketis, C. Samama, A. Dunn, 2022, Chest.

Key Articles and Guidelines in the Management of Peripheral Arterial Disease

P. Dobesh, T. Trujillo, Zachary A. Stacy, 2011 .

Reversing the anticoagulation effects of dabigatran

W. Dager, William E Dager, L. Banares, 2017, Hospital practice.

Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia.

W. Dager, A. Roberts, William E Dager, 2016, Thrombosis research.

Comparison of Bivalirudin Dosing Strategies Using Total, Adjusted, and Ideal Body Weights in Obese Patients with Heparin‐Induced Thrombocytopenia

W. Dager, William E Dager, L. Tsu, 2012, Pharmacotherapy.

Bivalirudin Dosing Adjustments for Reduced Renal Function with or Without Hemodialysis in the Management of Heparin-Induced Thrombocytopenia

W. Dager, William E Dager, L. Tsu, 2011, The Annals of pharmacotherapy.

Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion.

T. Trujillo, S. Haines, Stuart T Haines, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Issues in assessing and reducing the risk for venous thromboembolism.

W. Dager, William E Dager, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Dosing Nomograms: Silos on a Slope

William E Dager, 2009, The Annals of pharmacotherapy.

Variability of Plasma Anti-Xa Activities with Different Lots of Enoxaparin

J. T. Owings, E. Larkin, R. Gosselin, 2004, The Annals of pharmacotherapy.

Warfarin for Venous Thromboembolism Prophylaxis After Elective Hip or Knee Arthroplasty: Exploring the Evidence, Guidelines, and Challenges Remaining

W. Dager, William E Dager, 2012, The Annals of pharmacotherapy.

Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

E. Nutescu, A. Wittkowsky, William E Dager, 2009 .

Heparin‐Induced Thrombocytopenia: Treatment Options and Special Considerations

M. Militello, W. Dager, William E Dager, 2007, Pharmacotherapy.

Systemic Anticoagulant Prophylaxis for Central Catheter–Associated Venous Thrombosis in Cancer Patients

A. Chan, A. Iannucci, W. Dager, 2007, The Annals of pharmacotherapy.

Vitamin K Dosing to Reverse Warfarin Based on INR, Route of Administration, and Home Warfarin Dose in the Acute/Critical Care Setting

W. Dager, William E Dager, L. Tsu, 2012, The Annals of pharmacotherapy.

Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis

Brett H. Heintz, G. Matzke, B. Heintz, 2009, Pharmacotherapy.

Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

E. Nutescu, A. Wittkowsky, W. Dager, 2009 .

Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia.

J. T. Owings, T. Wun, Jufen Zhou, 2007, American journal of clinical pathology.

Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum

Arthur L. Allen, A. Rajasekhar, M. Crowther, 2022, Journal of Thrombosis and Thrombolysis.

Dosing guidelines, not protocols, for managing warfarin therapy.

S. Spinler, E. Nutescu, A. Wittkowsky, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The Joint Commission National Patient Safety Goals (NPSG) directing anticoagulation safety in the United States

R. Gosselin, Robert C. Gosselin, Aaron Roberts, 2019, Annals of Blood.

Tinzaparin in Outpatients with Pulmonary Embolism or Deep Vein Thrombosis

R. White, R. Ferrer, W. Dager, 2005, The Annals of pharmacotherapy.

What Are the Important Drug Use Errors in Dialysis Patients?

W. Dager, William E Dager, 2010, Seminars in dialysis.

Key Articles and Guidelines Relative to Intensive Care Unit Pharmacotherapy: 2009 Update

B. Erstad, J. Devlin, G. Brophy, 2009, Pharmacotherapy.

Aminoglycoside Pharmacokinetics: Volume of Distribution in Specific Adult Patient Subgroups

W. Dager, William E Dager, 1994, The Annals of pharmacotherapy.

Racial and gender differences in the incidence of recurrent venous thromboembolism

R. White, S. Murin, W. Dager, 2006, Thrombosis and Haemostasis.

Optimization of Inpatient Warfarin Therapy: Impact of Daily Consultation by a Pharmacist-Managed Anticoagulation Service

T. Albertson, R. White, R. White, 2000, The Annals of pharmacotherapy.

Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants.

W. Dager, William E Dager, Thaddaus R. Hellwig, 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations.

J. Lewin, M. Cipolle, J. Kalus, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Drug-induced thrombocytopenia in critically ill patients

W. Dager, William E Dager, M. Smythe, 2010, Critical care medicine.

Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews

J. Lovely, Siu-Fun Wong, R. Parrish, 2022, Journal of clinical medicine.

The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage.

J. Holmes, R. Schrot, D. Nishijima, 2010, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

Managing Complications of Anticoagulant Therapy

W. Dager, William E Dager, M. Smythe, 2004 .

Clinical Experience with Aminoglycosides in Dialysis-Dependent Patients: Risk Factors for Mortality and Reassessment of Current Dosing Practices

Brett H. Heintz, B. Heintz, W. Dager, 2011, The Annals of pharmacotherapy.

Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations

A. Flannery, W. Dager, William E Dager, 2017, Journal of Thrombosis and Thrombolysis.

Acute Kidney Injury

J. H. Maker, W. Dager, William E Dager, 2017 .

Considerations for Systemic Anticoagulation in ESRD

W. Dager, William E Dager, L. Tsu, 2015, Seminars in dialysis.

Safety of New Oral Anticoagulants with Dual Antiplatelet Therapy in Patients with Acute Coronary Syndromes

William E Dager, L. Tsu, 2013, The Annals of pharmacotherapy.

Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study

S. Kitchen, R. Gosselin, W. Dager, 2012, The Annals of pharmacotherapy.

Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support With or Without Continuous Renal Replacement Therapy

A. J. Roberts, W. Dager, William E Dager, 2019, ASAIO journal.

Response to: “More on the Limitations of the aPTT for Monitoring Argatroban Therapy”

E. V. Van Cott, W. Dager, William E Dager, 2017, Seminars in Thrombosis and Hemostasis.

Comparing Direct Thrombin Inhibitors Using aPTT, Ecarin Clotting Times, and Thrombin Inhibitor Management Testing

J. T. Owings, E. Larkin, R. Gosselin, 2004, The Annals of pharmacotherapy.

Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels

W. Dager, William E Dager, Sara Zochert, 2022, The Annals of pharmacotherapy.

Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach

D. W. Hawkins, P. Dobesh, E. Nutescu, 2006, The Annals of pharmacotherapy.

Low-Molecular-Weight Heparin–Induced Thrombocytopenia in a Child

R. White, W. Dager, William E Dager, 2004, The Annals of pharmacotherapy.

Argatroban for Heparin-Induced Thrombocytopenia in Hepato-Renal Failure and CVVHD

R. White, W. Dager, William E Dager, 2003, The Annals of pharmacotherapy.

Pharmacotherapy of heparin-induced thrombocytopenia

R. White, W. Dager, William E Dager, 2003, Expert opinion on pharmacotherapy.

Treatment of Heparin-Induced Thrombocytopenia

R. White, W. Dager, William E Dager, 2002, The Annals of pharmacotherapy.

Warfarin Initiation and Monitoring with Clotting Factors II, VII, and X

Ashley S Trask, R. Gosselin, W. Dager, 2004, The Annals of pharmacotherapy.

Special Considerations with Fondaparinux Therapy: Heparin‐Induced Thrombocytopenia and Wound Healing

E. Nutescu, J. Andersen, W. Dager, 2004, Pharmacotherapy.

Estimating Phenytoin Concentrations by the Sheiner-Tozer Method in Adults with Pronounced Hypoalbuminemia

W. Dager, William E Dager, J. Inciardi, 1995, The Annals of pharmacotherapy.

Bivalirudin in Pediatric Patients Maintained on Extracorporeal Life Support

J. Duby, R. Pretzlaff, Erin L Nagle, 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Effect of telavancin (Vibativ) on routine coagulation test results.

J. Gregg, D. Dwyre, R. Gosselin, 2011, American journal of clinical pathology.

Vitamin K Dosing to Reverse Warfarin Based on INR, Route of Administration, and Home Warfarin Dose in the Acute/Critical Care Setting

William E Dager, Tsu Lv, Dienes Je, 2012, The Annals of pharmacotherapy.

Transitioning from Traditional to Novel Anticoagulants: The Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Management

S. Spinler, H. Bussey, E. Nutescu, 2004, Pharmacotherapy.

Dosing guidelines, not protocols, for managing warfarin therapy.

S. Spinler, E. Nutescu, A. Wittkowsky, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

"Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy": Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance.

J. Ansell, S. Kaatz, S. Deitelzweig, 2020, Joint Commission journal on quality and patient safety.

Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy

S. Spinler, J. Fanikos, E. Nutescu, 2013, Pharmacotherapy.

Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness

S. Spinler, J. Fanikos, E. Nutescu, 2011, Pharmacotherapy.

Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity

R. Gosselin, W. Dager, A. Roberts, 2013, Critical care medicine.

Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.

A. J. Roberts, D. Nishijima, W. Dager, 2019, Thrombosis research.

Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

E. Nutescu, A. Wittkowsky, William E Dager, 2009 .

Developing a management plan for oral anticoagulant reversal.

W. Dager, William E Dager, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Title Considerations for Systemic Anticoagulation in ESRD Permalink

W. Dager, William E Dager, L. Tsu, 2015 .